Literature DB >> 26171200

Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: A meta-analysis.

Shi-Ji Xiao1, Jian-Zhen Shen1, Jin-Long Huang1, Hai-Ying Fu1.   

Abstract

Numerous studies have investigated the prognostic role of brain and acute leukemia, cytoplasmic (BAALC) gene expression in adult patients with acute myeloid leukemia (AML); however, the results are inconclusive. A meta-analysis was conducted to provide a comprehensive evaluation of the prognostic role of BAALC gene expression in AML. Eligible studies were searched through PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure and the China Biology Medicine Disc. Correlations between the BAALC gene expression and clinicopathological features and prognosis were analyzed. A total of 15 studies were examined. The pooled results suggest that high BAALC expression had an unfavorable outcome in AML. The combined hazard ratio (HR) for overall survival (OS) was 1.53 and the summary HR for the disease-free survival rate was 1.64. In addition, subgroup analyses considering cytogenetic and survival analysis were also conducted. High BAALC gene expression appeared to be an adverse prognostic indicator in patients with cytogenetically normal AML (HR for OS, 1.43) and in subgroups of survival analysis with multivariate analysis (HR for OS, 2.35). These results indicate that high BAALC gene expression served as an independent poor prognostic indicator in adult patients with AML.

Entities:  

Keywords:  acute myeloid leukemia; brain and acute leukemia cytoplasmic gene; meta-analysis; prognosis

Year:  2015        PMID: 26171200      PMCID: PMC4486884          DOI: 10.3892/mco.2015.562

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  33 in total

1.  Prognostic implication of BAALC gene expression in adult acute myeloid leukemia.

Authors:  Raida S Yahya; Mamdouh A Sofan; Hanaa M Abdelmasseih; Niveen Saudy; Mohamed A Sharaf-Eldein
Journal:  Clin Lab       Date:  2013       Impact factor: 1.138

Review 2.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

3.  Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

Authors:  Frederik Damm; Michael Heuser; Michael Morgan; Katharina Wagner; Kerstin Görlich; Anika Grosshennig; Iyas Hamwi; Felicitas Thol; Ewa Surdziel; Walter Fiedler; Michael Lübbert; Lothar Kanz; Christoph Reuter; Gerhard Heil; Ruud Delwel; Bob Löwenberg; Peter J M Valk; Jürgen Krauter; Arnold Ganser
Journal:  Blood       Date:  2011-03-03       Impact factor: 22.113

4.  Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.

Authors:  Jehan A El-Sharnouby; Laila M Sayed Ahmed; Atef M Taha; Oqasha Kamal
Journal:  Egypt J Immunol       Date:  2008

5.  Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Authors:  Marianne Bienz; Madleina Ludwig; Elisabeth Oppliger Leibundgut; Beatrice U Mueller; Daniel Ratschiller; Max Solenthaler; Martin F Fey; Thomas Pabst
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

Review 6.  Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.

Authors:  M Port; M Böttcher; F Thol; A Ganser; R Schlenk; J Wasem; A Neumann; L Pouryamout
Journal:  Ann Hematol       Date:  2014-05-07       Impact factor: 3.673

7.  ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.

Authors:  Klaus H Metzeler; Annika Dufour; Tobias Benthaus; Manuela Hummel; Maria-Cristina Sauerland; Achim Heinecke; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Jan Braess; Karsten Spiekermann; Wolfgang Hiddemann; Christian Buske; Stefan K Bohlander
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

8.  Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.

Authors:  Jae-Ho Yoon; Hee-Je Kim; Seung-Hwan Shin; Seung-Ah Yahng; Sung-Eun Lee; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chong-Won Park; Ji-Hyang Lim
Journal:  Leuk Lymphoma       Date:  2013-06-12

9.  BAALC, a novel marker of human hematopoietic progenitor cells.

Authors:  Claudia D Baldus; Stephan M Tanner; Donna F Kusewitt; Sandya Liyanarachchi; Changsun Choi; Michael A Caligiuri; Clara D Bloomfield; Albert de la Chapelle
Journal:  Exp Hematol       Date:  2003-11       Impact factor: 3.084

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  3 in total

1.  Role of BAALC Gene in Prognosis of Acute Lymphoblastic Leukemia in Egyptian Children.

Authors:  Adel A Hagag; Walid A Elshehaby; Nahd M Hablas; Mohamed M Abdelmageed; Amal Ezzat Abd El-Lateef
Journal:  Indian J Hematol Blood Transfus       Date:  2017-06-23       Impact factor: 0.900

2.  Application of the AMLprofiler Diagnostic Microarray in the South African Setting.

Authors:  S S Kappala; M Alessandrini; T Matlhako; E Beltchev; R Pool; M S Pepper
Journal:  Stem Cells Int       Date:  2017-11-07       Impact factor: 5.443

3.  The modular network structure of the mutational landscape of Acute Myeloid Leukemia.

Authors:  Mariam Ibáñez; José Carbonell-Caballero; Esperanza Such; Luz García-Alonso; Alessandro Liquori; María López-Pavía; Marta Llop; Carmen Alonso; Eva Barragán; Inés Gómez-Seguí; Alexander Neef; David Hervás; Pau Montesinos; Guillermo Sanz; Miguel Angel Sanz; Joaquín Dopazo; José Cervera
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.